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Abstract
Objective: Summarize data on metabolic syndrome (MS) in bipolar disorder (BD). Methods: A 
systematic review of the literature was conducted using the Medline, Embase and PsycInfo 
databases, using the keywords “metabolic syndrome”, “insulin resistance” and “metabolic X 
syndrome” and cross-referencing them with “bipolar disorder” or “mania”. The following types of 
publications were candidates for review: (i) clinical trials, (ii) studies involving patients diagnosed 
with bipolar disorder or (iii) data about metabolic syndrome. A 5-point quality scale was used to 
assess the methodological weight of the studies. Results: Thirty-nine articles were selected. None 
of studies reached the maximum quality score of 5 points. The prevalence of MS was significantly 
higher in BD individuals when compared to a control group. The analysis of MS subcomponents 
showed that abdominal obesity was heterogeneous. Individuals with BD had significantly higher 
rates of hypertriglyceridemia than healthy controls. When compared to the general population, 
there were no significant differences in the prevalence of low HDL-c in individuals with BD. Data 
on hypertension were also inconclusive. Rates of hyperglycemia were significantly greater in 
patients with BD compared to the general population. Conclusions: The overall results point to 
the presence of an association between BD and MS, as well as between their subcomponents.
© 2013 Associação Brasileira de Psiquiatria. Published by Elsevier Editora Ltda. All rights reserved.
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Introduction
Bipolar disorder (BD) is a chronic disease characterized 
by extreme changes in mood polarity. Onset typically 
occurs between adolescence and early adulthood. 
BD is associated with impairments in social and 
neuropsychological development, resulting in a high 
level of overall impairment. BD is the sixth leading cause 
of disability in the world and has a global prevalence 
estimated at .8%.1 
In addition to the psychiatric symptoms associated with 
BD, there is also evidence suggesting that BD patients are 
at increased risk for clinical diseases in comparison to 
healthy controls. A sedentary lifestyle, smoking, and an 
unhealthy diet are prejudicial factors, as are metabolic 
disorders and neurological/cardiovascular diseases.2 As 
a result, patients with BD have a life expectancy that is 
reduced by 25 to 30 years.3
Among the clinical diseases that are comorbid 
with BD, there is evidence of a high rate of metabolic 
syndrome (MS) in bipolar patients. MS is collection of 
metabolic risk factors with an unknown etiologic basis and 
pathophysiological mechanisms that increases the chances 
of developing cardiovascular disease and type 2 diabetes.3 
The prevalence of MS in the world population ranges from 
6.0% to 70.3%, depending on variables such as diagnosis 
criteria, comorbidities, ethnic group and sex.4
In bipolar patients, MS comorbidity is associated with 
a more complex disease, a less favorable response to 
treatment, and adverse courses and outcomes, such as 
an increased risk for depressive symptoms and episodes, 
including the risk of suicide.5,6 
Thus, the aim of this study is to summarize data on 
metabolic syndrome in patients with BD.
Methods
To identify studies that are relevant to the current 
study, a systematic review was conducted with the 
Medline, Embase and PsycInfo databases, using the 
keywords “metabolic syndrome”, “insulin resistance” 
and “metabolic X syndrome”, and cross-referencing 
them with “bipolar disorder” or “mania”. The search was 
conducted during May of 2012 and was limited to human 
studies published in English. Duplicated articles were 
excluded. The remaining paper titles and abstracts 
were used to determine whether the reference might be 
pertinent to the review. The following types of publications 
were candidates for review: (i) clinical trials, (ii) studies 
involving patients diagnosed with bipolar disorder, or (iii) 
data about metabolic syndrome. 
To assess the methodological weight of the studies, 
a 5-point quality scale was used that included the 
following items: a sample with at least 100 BD patients, 
a standardized BD diagnostic measure, use of the NCEP 
National Cholesterol Education Program (NCEP) or the 
International Diabetes Federation (IDF) criteria for MS, 
and a central aim of evaluating MS in BD patients or 
of comparing BD patients to controls or data from the 
general population. This quality score was based on a 
similar scoring method that used for two other published 
review articles relevant to the current study.7,8
Results
Search results
The literature search conducted using Medline, Embase and 
PsycInfo resulted in 457 articles. After the duplicate articles 
were excluded, 70 titles and abstracts were evaluated for 
pertinence. This process resulted in 39 references that were 
relevant to the present literature review. The search chart is 
shown in Figure 1, and the data extracted from these studies 
is available online as Supplementary Information. 
Quality of studies
None of the studies reached the maximum quality rating of 
5 points, mainly due to the lack of a structured BD diagnostic 
measure, the lack of a control group or general population 
comparison, or a sample size of less than 100 BD subjects.
Prevalence and demographic features
The prevalence of MS in BD patients was distributed according 
to different criteria, as presented in Table 1.
Patients with BD had a slightly higher rate of MS compared 
to the general population, but this difference failed to reach 
significance.9-12 However, when compared to a control group, 
the prevalence of MS was significantly higher in BD patients.12-16
BD patients with MS were significantly older than BD 
patients without MS.14,17-21 The risk of MS increased more than 
3 times in BD subjects over 30 years old12,19 when compared to 
a control group.15,16 However, one study showed no association 
of MS with age.9 There were no significant differences in MS 
rates according to gender.6,9,10,14-17,20-31 
Search results
(n = 457)
Retrieved for full-
text evaluation 
(n = 70)
Excluded after title and abstratct 
analysis 
(n = 387)
 
Exclusion criteria 
(n = 31)
- Theoretical articles and reviews
- Samples include BD and other
 disorders without discriminate  
 analysis
- Metabolic syndrome data not  
 presented
Selected for 
review 
(n = 39)
Figure 1 Flowchart of methods.
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Although some previous studies have found significantly 
higher obesity rates in BD patients compared to the general 
population11 or healthy controls,12 others have found a 
significant difference only in women10  or no difference 
at all.33 Data on the differences in gender prevalence 
are similarly conflicting; in two studies, female patients 
had significantly higher prevalence rates of abdominal obesity 
when compared to men,21,22 whereas another study showed 
no such difference.6
BD patients had significant higher rates of hypertri-
glyceridemia than controls.12,14-16,33 When compared to 
the general population, there was no significant differ-
ence.10 Male BD patients had significantly higher rates 
of hypertriglyceridemia when compared to female BD 
patients.6,22 
Some studies presented significantly higher prevalence 
rates of low HDL-c in BD patients when compared to 
controls,14-16,33 contrary to other reports that showed no 
significant difference.11,12 The prevalence of low HDL-c was 
lower in BD patients compared to the general population, 
but that was not significantly different.10 Women had higher 
rates of low HDL-c than did men, but this was not statistically 
significant.6,22 Women did have significantly higher HDL-c 
ratios when compared to men.40 
Data on hypertension were also contradictory. Although 
one study showed similar prevalence rates in patients with 
BD and the general population,10 another showed significant 
higher prevalence in patients.11 When compared to controls, 
one study presented significantly higher rates of hypertension 
in patients,14 whereas others reported similar prevalence 
rates.12,15,16 Among BD patients, men had significantly 
higher rates of hypertension than women,6,22 with 
significantly higher systolic blood pressures as well.40
Despite the selectivity of the criteria used, 
hyperglycemia rates were significantly higher in patients 
with BD when compared to the general population.10 However, 
when compared to controls, patients had a similar prevalence 
of hyperglycemia.12,14-16,33 Men and women had similar rates of 
hyperglycemia.6,22
Obesity was higher in patients with BD than controls12,15,16 
and the general population9,11 (except in one study that 
found similar prevalence rates in both groups10). BD patients 
were also reported to be more overweight than controls, 
both significantly14 and non-significantly,12 and they were 
significantly more overweight than the general population.11 
Patients with MS had significantly higher body mass index 
(BMI) values than those without MS,18 and it was found 
that BMI was significantly associated with MS in a logistic 
regression analysis.19
Discussion
Despite finding some contradictory results, we report on a 
body of evidence that shows a higher prevalence of MS and 
its subcomponents in bipolar patients. MS was associated with 
a poor course of illness and prognosis in bipolar individuals, 
suggesting that this is still an important issue in clinical and 
psychiatric practice.
Table 1 Prevalence of metabolic syndrome in bipolar 
disorder in each criterion definition.
Criterion Prevalence References
NCEP ATP III 16.7%-50.0% 10; 12; 14-17; 19; 20; 22; 23; 25; 26; 
28-32; 34; 36; 52; 53
IDF 25.7%-67.0% 12; 19; 20; 39; 51
NCEP ATP III: National Cholesterol Education Program Adult Treatment Panel
IDF: International Diabetes Federation.
Course of disorder and clinical outcomes
Two studies of BD patients reported no significant differences 
in the age of onset of the first episode in BD patients with 
MS compared to those without MS.6,20 However, Guan et al.13 
found that BD patients with MS had a significantly older mean 
age of onset of the first episode compared to BD patients 
without MS. Other studies showed that BD patients with MS 
had a significantly later age of first treatment for depression 
and mania,6 a significantly longer illness duration20 and a 
significantly greater number of psychiatric hospitalizations,6 
compared to those without MS. 
Several studies found no association between psychotropic 
drug use or treatment strategy and elevated rates of 
MS.10,12,14,22,32-34 However, more of the subjects taking 
olanzapine, clozapine, or lithium met criteria for MS than 
those who did not take these drugs.17,35 Patients taking only 
antipsychotics had higher MS rates than patients taking 
only mood stabilizers.24
The rates of psychiatric comorbidity were not significantly 
different between BD patients with and without MS,6,20 but 
BD patients did have significantly higher rates of psychiatric 
comorbidities compared with healthy controls.16 Some studies 
showed no significant difference in the lifetime history of 
suicide attempts between BD patients with and without 
MS,6,9,23,36 whereas others found that this was significantly 
higher in BD patients with MS.36,37
With regards to clinical comorbidities, BD patients had 
higher overall comorbidity rates than healthy controls.15,16 
BD patients with MS had significantly increased rates of 
diabetes and cardiovascular disease compared to both BD 
patients without MS14,18,22 and to the general population.11 
These patients also had a significantly greater risk of 
cardiovascular mortality and coronary heart disease when 
compared to patients without MS.38 Smoking was not 
associated with the presence14,20 or risk of MS,39 except when 
compared to controls or the general population.11,16 Bipolar 
patients with MS had significantly higher rates of alcoholism 
than patients without MS,14 but they had similar alcoholism 
rates as controls16 and significantly lower alcoholism rates 
than other diagnostic criteria.35
Subcomponents of metabolic syndrome
In the analysis of MS subcomponents, the findings on 
abdominal obesity were inconclusive. 
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The variance in results could be explained by differences 
in the sample or could reflect differences in the prevalence 
of MS in the general population due to cultural differences 
in dietary habits, levels of physical activity and genetic 
backgrounds. These factors may have influenced the analysis 
of the subcomponents as well. Indeed, the heterogeneity of 
the criteria is a significant concern regarding MS diagnosis41 
and could have affected the prevalence rates in the reviewed 
studies. The criteria by the NCEP ATP III and the IDF are 
the most widely used to diagnose MS, but there are some 
differences between them (Table 2). Moreover, there is a 
large cluster of criteria modifications that makes clinical 
diagnosis and research analysis challenging. 
Although the use of psychotropic drugs provides a 
common-sense explanation of some of the components 
of MS, studies that do not find this association show that 
medications are not a simple explanation. Most BD patients 
reported polypharmaceutical drug use or had used different 
types of medication during the course of their disease. 
Because antipsychotic polytherapy increases the prevalence 
of MS compared to monotherapy,42 the use of multiple 
medications could aggravate the course of MS, resulting in 
a worse outcome.35 However, the co-occurrence of BD with 
obesity and changes in glucose metabolism are observed even 
before the existence of these medications.11 A study with 
first-episode psychotic patients showed increasing rates of 
obesity, hyperglycemia and dyslipidemia after using atypical 
antipsychotics.43 Studies with first-episode or drug-free BD 
patients are required to clarify the role of medication in 
this association.
Mechanisms linking MS and bipolar disorder have been 
largely unidentified. Hypotheses have emerged positing that 
both negative health behaviors, such as smoking, poor diet, 
overeating, and a sedentary lifestyle,44 and biological factors 
of MS, such as hypothalamic-pituitary-adrenocortical (HPA) 
axis and sympathoadrenal hyperactivity, and abnormalities of 
the immunologic system,45 such as increased proinflammatory 
cytokines,46 are correlated with BD.  
Negative outcomes such as psychiatric and physical 
comorbidities could also be explained by the concept 
of allostatic load (AL). AL results from an overload in 
the allostatic processes due to the chronic overactivity 
or inactivity of the physiological systems (such as the 
hypothalamic-pituitary-adrenal axis) that are involved in 
the capacity to achieve stability through adaptation to 
internal and external demands (i.e., allostasis). Patients 
with a higher AL were found to have an increased risk of 
incidental cardiovascular disease and all-cause mortality, 
which is in accordance with the increased prevalence in 
found in BD patients of medical conditions such as diabetes, 
hypertension, ischemic heart disease and stroke.47 All of 
those correlated factors, such as neuroendocrinal and 
inflammatory abnormalities, the use of psychotropic drugs 
and negative health behaviors, act like allostatic components 
that reinforce the role of AL in BD-MS association. 
Several limitations were noted during the review of 
the cited articles in the current study. First, differing 
experimental designs and sampling methodologies make 
formal comparison between studies difficult. Different 
criteria used to diagnose MS and the lack of a structured 
diagnostic interview to confirm a bipolar diagnosis did 
not allow for standardization of the results. Additionally, 
most of the studies were cross-sectional. Because of this 
limitation, a causal relationship between bipolar disorder 
and metabolic syndrome could not be established. The 
medication treatment regimen may also be a liability, evoking 
the need for longitudinal studies.  
In conclusion, the association between MS and BD, 
although not clear, is important to consider, as BD patients 
have other risks factors for MS, such as increased rates of 
cardiovascular disease and diabetes. Because cardiovascular 
risk is increased in bipolar patients, and because of the 
negative impact of MS on general physical and psychological 
well-being and functioning, MS could contribute to a worse 
prognosis for BD and vice-versa. Therefore, psychiatrists 
should be aware of the risk factors involved in MS 
and should intervene as soon as possible to prevent metabolic 
Table 2 NCEP and IDF definitions for metabolic syndrome.
Risk factors NCEP levels (2002) NCEP III modified (2005) IDF levels (2006)
Abdominal obesity WC > 102 for men 
WC > 88 for women
WC > 102 for men 
WC > 88 for women
WC ≥ 94 cm for men (Europe)
WC ≥ 80 cm for women 
or BMI > 30 kg/m2
Triglycerides
≥ 150 mg/dL ≥ 150 mg/dL (1.7 mmol/L) ≥ 150 mg/dL (1.7 mmol/L)
or specific treatment for this lipid abnormality
HDL-cholesterol < 40 mg/dL for men
< 50 mg/dL for women
< 40 mg/dL (1.03 mmol/L in men
< 50 mg/dL (1.29 mmol/L) in women
< 40 mg/dL (1.03 mmol/L in men
< 50 mg/dL (1.29 mmol/L) in women
or specific treatment for this lipid abnormality
Blood pressure ≥ 130/85 mmHg ≥130/85 mmHg
or current use of antihypertensive drugs
≥130/85 mmHg
or treatment of previously diagnosed hypertension 
Fasting glucose ≥ 110 mg/dL ≥ 100 mg/dL (5.6 mmol/L) ≥ 100 mg/dL (5.6 mmol/L) 
or previous diagnosis of type 2 diabetes 
NCEP ATP III: National Cholesterol Education Program  Adult Treatment Panel; IDF: International Diabetes Federation; WC: waist circumference;  
BMI: body mass index.
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abnormalities that could influence the prognosis of bipolar 
disorder. Such strategies include monitoring the patient’s 
lifestyle, eating habits and exercise routine.
Disclosures
Letícia Czepielewski
Employment: Developmental Cognitive Neuroscience Research Group, 
Post-Graduate Program in Psychology and The Biomedical Research 
Institute of Pontíficia Universidade do Rio Grande do Sul, Porto Alegre, 
Brazil.
Ledo Daruy Filho, M.D., M.Sc
Employment: Developmental Cognitive Neuroscience Research Group, 
Post-Graduate Program in Psychology and The Biomedical Research 
Institute of Pontíficia Universidade do Rio Grande do Sul, Porto Alegre, 
Brazil.
Elisa Brietzke, MD, PhD
Employment: Program for Recognition and Intervention in Individuals in 
At-Risk Mental States, Department of Psychiatry, Universidade Federal 
de São Paulo, São Paulo, Brazil; Interdisciplinary Laboratory of Clinical 
Neurosciences (LiNC), Department of Psychiatry, Universidade Federal 
de São Paulo, São Paulo, Brazil.
Rodrigo Grassi-Oliveira, MD, PhD
Employment: Developmental Cognitive Neuroscience Research Group, 
Post-Graduate Program in Psychology and The Biomedical Research 
Institute of Pontíficia Universidade do Rio Grande do Sul, Porto Alegre, 
Brazil.
The authors report no proprietary or commercial interest in any product 
mentioned or concept discussed in this article.
* Modest
** Significant
*** Significant. Amounts given to the author's institution or to a colleague for 
research in which the author has participation, not directly to the author.
References 
1. Ferrari AJ, Baxter AJ, Whiteford HA. A systematic review of the 
global distribution and availability of prevalence data for bipolar 
disorder. J Affect Disord. 2011;134(1-3):1-13.
2. Brietzke E, Kapczinski F, Grassi-Oliveira R, Grande I, Vieta E, 
McIntyre RS. Insulin dysfunction and allostatic load in bipolar 
disorder. Expert Rev Neurother. [Review]. 2011;11(7):1017-28.
3. de Almeida KM, Moreira CL, Lafer B. Metabolic syndrome and 
bipolar disorder: what should psychiatrists know? CNS Neurosci 
Ther. 2012;18(2):160-6.
4. Eberly LE, Prineas R, Cohen JD, Vazquez G, Zhi X, Neaton JD, 
et al. Metabolic syndrome: risk factor distribution and 18-year 
mortality in the multiple risk factor intervention trial. Diabetes 
Care. [Multicenter Study Research Support, N.I.H., Extramural]. 
2006;29(1):123-30.
5. McIntyre RS, Danilewitz M, Liauw SS, Kemp DE, Nguyen HT, 
Kahn LS, et al. Bipolar disorder and metabolic syndrome: an 
international perspective. J Affect Disord. [Comparative Study 
Review]. 2010;126(3):366-87.
6. McIntyre RS, Woldeyohannes HO, Soczynska JK, Miranda A, 
Lachowski A, Liauw SS, et al. The rate of metabolic syndrome 
in euthymic Canadian individuals with bipolar I/II disorder. Adv 
Ther. 2010;27(11):828-36.
7. Fisher HL, Hosang GM. Childhood Maltreatment and Bipolar 
Disorder: A Critical Review of the Evidence. Mind Brain [serial 
on the Internet]. 2010.
8. Daruy-Filho L, Brietzke E, Lafer B, Grassi-Oliveira R. Childhood 
maltreatment and clinical outcomes of bipolar disorder. Acta 
Psychiatr Scand. 2011;124(6):427-34.
9. Almeida K, Macedo-Soares M, Issler C, Amaral J, Caetano S, Dias 
R, et al. Obesity and metabolic syndrome in Brazilian patients 
with bipolar disorder. Acta Neuropsychiatrica. 2009;2:84-8.
10. Baptista T, Serrano A, Uzcategui E, ElFakih Y, Rangel N, Carrizo 
E, et al. The metabolic syndrome and its constituting variables in 
atypical antipsychotic-treated subjects: comparison with other 
drug treatments, drug-free psychiatric patients, first-degree 
relatives and the general population in Venezuela. Schizophr 
Res. 2011;126(1-3):93-102.
11. Birkenaes AB, Opjordsmoen S, Brunborg C, Engh JA, Jonsdottir 
H, Ringen PA, et al. The level of cardiovascular risk factors in 
bipolar disorder equals that of schizophrenia: a comparative 
study. J Clin Psychiatry. 2007;68(6):917-23.
12. Lee NY, Kim SH, Cho B, Lee YJ, Chang JS, Kang UG, et al. 
Patients taking medications for bipolar disorder are more prone 
to metabolic syndrome than Korea's general population. Prog 
Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1243-9.
13. Guan N, Liu H, Diao F, Zhang J, Zhang M, Wu T. Prevalence of 
metabolic syndrome in bipolar patients initiating acute-phase 
treatment: a 6-month follow up. Psychiatry Clin Neurosci. 
2010;64(6):625-33.
14. Sicras-Mainar A, Blanca-Tamayo M, Rejas-Gutierrez J, Navarro-
Artieda R. Metabolic syndrome in outpatients receiving 
antipsychotic therapy in routine clinical practice: a cross-
sectional assessment of a primary health care database. Eur 
Psychiatry. 2008;23(2):100-8.
15. Sicras A, Rejas J, Navarro R, Serrat J, Blanca M. Metabolic 
syndrome in bipolar disorder: a cross-sectional assessment of 
a Health Management Organization database. Bipolar Disord. 
2008;10(5):607-16.
16. Cardenas J, Frye MA, Marusak SL, Levander EM, Chirichigno JW, 
Lewis S, et al. Modal subcomponents of metabolic syndrome 
in patients with bipolar disorder. J Affect Disord. 2008;106(1-
2):91-7.
17. Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic 
syndrome and the risk of coronary heart disease in 367 patients 
treated with second-generation antipsychotic drugs. J Clin 
Psychiatry. 2006;67(4):575-83.
18. Garcia-Portilla MP, Saiz PA, Benabarre A, Sierra P, Perez J, 
Rodriguez A, et al. The prevalence of metabolic syndrome in 
patients with bipolar disorder. J Affect Disord. 2008;106(1-
2):197-201.
19. Salvi V, Albert U, Chiarle A, Soreca I, Bogetto F, Maina G. 
Metabolic syndrome in Italian patients with bipolar disorder. 
Gen Hosp Psychiatry. 2008;30(4):318-23.
20. van Winkel R, De Hert M, Van Eyck D, Hanssens L, Wampers 
M, Scheen A, et al. Prevalence of diabetes and the metabolic 
syndrome in a sample of patients with bipolar disorder. Bipolar 
Disord. 2008;10(2):342-8.
21. Salvi V, D'Ambrosio V, Rosso G, Bogetto F, Maina G. Age-specific 
prevalence of metabolic syndrome in Italian patients with 
bipolar disorder. Psychiatry Clin Neurosci. 2011;65(1):47-54.
22. Vuksan-Cusa B, Sagud M, Jakovljevic M. C-reactive protein 
and metabolic syndrome in patients with bipolar disorder 
compared to patients with schizophrenia. Psychiatr Danub. 
2010;22(2):275-7.
23. Yumru M, Savas HA, Kurt E, Kaya MC, Selek S, Savas E, et al. 
Atypical antipsychotics related metabolic syndrome in bipolar 
patients. J Affect Disord. 2007;98(3):247-52.
24. Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased 
risk for metabolic syndrome in patients with bipolar disorder and 
schizophrenia treated with second-generation antipsychotics. 
Bipolar Disord. 2008;10(7):788-97.
25. D'Ambrosio V, Salvi V, Bogetto F, Maina G. Serum lipids, 
metabolic syndrome and lifetime suicide attempts in patients 
with bipolar disorder. Prog Neuropsychopharmacol Biol 
Psychiatry. 2012;37(1):136-40.
26. Ezzaher A, Haj MD, Mechri A, Neffati F, Douki W, Gaha L, et al. 
Metabolic syndrome in Tunisian bipolar I patients. Afr Health 
Sci. 2011;11(3):414-20.
93Bipolar disorder and metabolic syndrome
27. Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, Miller 
DD, Haynes WG. Elevated prevalence of obesity, metabolic 
syndrome, and cardiovascular risk factors in bipolar disorder. 
Ann Clin Psychiatry. 2008;20(3):131-7.
28. Grover S, Aggarwal M, Dutt A, Chakrabarti S, Avasthi A, Kulhara 
P, et al. Prevalence of metabolic syndrome in patients with 
schizophrenia in India. Psychiatry Res. 2012;200:1035-7.
29. Khatana SA, Kane J, Taveira TH, Bauer MS, Wu WC. Monitoring 
and prevalence rates of metabolic syndrome in military veterans 
with serious mental illness. PLoS One. 2011;6(4):e19298.
30. Salvi V, D'Ambrosio V, Bogetto F, Maina G. Metabolic syndrome in 
Italian patients with bipolar disorder: a 2-year follow-up study. 
J Affect Disord. 2012;136(3):599-603.
31. Vuksan-Cusa B, Jakovljevic M, Sagud M, Mihaljevic Peles 
A, Marcinko D, Topic R, et al. Metabolic syndrome and 
serum homocysteine in patients with bipolar disorder and 
schizophrenia treated with second generation antipsychotics. 
Psychiatry Res. 2011;189(1):21-5.
32. Elmslie JL, Porter RJ, Joyce PR, Hunt PJ, Shand BI, Scott RS. 
Comparison of insulin resistance, metabolic syndrome and 
adiponectin in overweight bipolar patients taking sodium 
valproate and controls. Aust N Z J Psychiatry. 2009;43(1):53-60.
33. Kemp DE, Calabrese JR, Tran QV, Pikalov A, Eudicone JM, 
Baker RA. Metabolic syndrome in patients enrolled in a clinical 
trial of aripiprazole in the maintenance treatment of bipolar 
I disorder: a post hoc analysis of a randomized, double-blind, 
placebo-controlled trial. J Clin Psychiatry. 2010;71(9):1138-44.
34. Teixeira PJ, Rocha FL. The prevalence of metabolic syndrome 
among psychiatric inpatients in Brazil. Rev Bras Psiquiatr. 
2007;29(4):330-6.
35. Fagiolini A, Frank E, Turkin S, Houck PR, Soreca I, Kupfer DJ. 
Metabolic syndrome in patients with bipolar disorder. J Clin 
Psychiatry. 2008;69(4):678-9.
36. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic 
syndrome in bipolar disorder: findings from the Bipolar Disorder 
Center for Pennsylvanians. Bipolar Disord. 2005;7(5):424-30.
37. Garcia-Portilla MP, Saiz PA, Bascaran MT, Martinez AS, Benabarre 
A, Sierra P, et al. Cardiovascular risk in patients with bipolar 
disorder. J Affect Disord. 2009;115(3):302-8.
38. Garcia-Portilla MP, Saiz PA, Benabarre A, Florez G, Bascaran 
MT, Diaz EM, et al. Impact of substance use on the physical 
health of patients with bipolar disorder. Acta Psychiatr Scand. 
2010;121(6):437-45.
39. Chang HH, Chou CH, Chen PS, Gean PW, Huang HC, Lin CY, et 
al. High prevalence of metabolic disturbances in patients with 
bipolar disorder in Taiwan. J Affect Disord. 2009;117(1-2):124-9.
40. Correll CU, Frederickson AM, Kane JM, Manu P. Does 
antipsychotic polypharmacy increase the risk for metabolic 
syndrome? Schizophr Res. 2007;89(1-3):91-100.
41. Assmann G, Guerra R, Fox G, Cullen P, Schulte H, Willett D, 
et al. Harmonizing the definition of the metabolic syndrome: 
comparison of the criteria of the Adult Treatment Panel III and 
the International Diabetes Federation in United States American 
and European populations. Am J Cardiol. 2007;99(4):541-8.
42. Katon WJ. Clinical and health services relationships between 
major depression, depressive symptoms, and general medical 
illness. Biol Psychiatry. 2003;54(3):216-26.
43. Graham KA, Cho H, Brownley KA, Harp JB. Early treatment-
related changes in diabetes and cardiovascular disease risk 
markers in first episode psychosis subjects. Schizophr Res. 
2008;101(1-3):287-94.
44. Joynt KE, Whellan DJ, O'Connor CM. Depression and 
cardiovascular disease: mechanisms of interaction. Biol 
Psychiatry. 2003;54(3):248-61.
45. Taylor V, MacQueen G. Associations between bipolar disorder 
and metabolic syndrome: A review. J Clin Psychiatry. 
2006;67(7):1034-41.
46. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation 
and the phenomenology, pathophysiology, comorbidity, and 
treatment of bipolar disorder: a systematic review of the 
literature. J Clin Psychiatry. 2009;70(8):1078-90.
47. Kapczinski F, Vieta E, Andreazza AC, Frey BN, Gomes FA, 
Tramontina J, et al. Allostatic load in bipolar disorder: 
implications for pathophysiology and treatment. Neurosci 
Biobehav Rev. 2008;32(4):675-92.
48. Correll CU, Druss BG, Lombardo I, O'Gorman C, Harnett JP, 
Sanders KN, et al. Findings of a U.S. national cardiometabolic 
screening program among 10,084 psychiatric outpatients. 
Psychiatr Serv. 2010;61(9):892-8.
49. Taylor V, McKinnon MC, Macdonald K, Jaswal G, Macqueen GM. 
Adults with mood disorders have an increased risk profile for 
cardiovascular disease within the first 2 years of treatment. 
Can J Psychiatry. 2010;55(6):362-8.
50. Centorrino F, Mark TL, Talamo A, Oh K, Chang J. Health and 
economic burden of  metabolic comorbidity among individuals 
with bipolar disorder. J Clin Psychopharmacol. 2009;29(6):595-
600.
51. John AP, Koloth R, Dragovic M, Lim SC. Prevalence of metabolic 
syndrome among  Australians with severe mental illness. Med J 
Aust. 2009;190(4):176-9.
52. Vuksan-Cusa B, Marcinko D, Nad S, Jakovljević M. Differences 
in cholesterol and metabolic syndrome between bipolar 
disorder men with and without suicide attempts. Prog 
Neuropsychopharmacol Biol Psychiatry. 2009;33(1):109-12.
53. McIntyre RS, Woldeyohannes HO, Soczynska JK, Miranda A, 
Lachowski A, Liauw SS, et al. The rate of metabolic syndrome 
in euthymic Canadian individuals with bipolar I/II disorder. Adv 
Ther. 2010;27(11):828-36.
